Resmetirom AASLD Clinical Data Review Tuesday, November 16th, 2021 8.00 – 9.00am EST Forward Looking Statements Any statements, other than statements of historical facts, made in this presentation are, or may be deemed, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include those concerning: our primary and secondary study endpoints and supportive data for resmetirom, and the potential for achieving such end ...

Product Theater : "Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials." Dr. Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, San Antonio, Texas, and Visiting Professor of Hepatology, Oxford University, and Principal Investigator of the MAESTRO studies AASLD 2020 Conflicts Advisory Board/Panel: Akero, Altimmune, Arrowhead, Axcella, Blade Therapeutics, Cirius, Civi Biotherma, CLDF, Cymabay, Echosens, Foresite Labs, Galectin, Galmed, Gelesis, Genfi ...